Lots of late news from the drug makers. CNBC’s Mike Huckman has the latest.
There are 3 big pieces of information that Mike Huckman feels investors should know about. They follow:
Eli Lilly (LLY) is halting patient enrollment in 2 small clinical trials for Prasugrel, a blood-clotting drug that would have competed with Plavix. The company isn’t giving many details and Huckman adds that investors are spooked by the news.
Sales of Amgen’s (AMGN) top-selling drug Aransep fell 23%. Now, Amgen’s only great hope is a late stage developmental drug for osteoperosis says Huckman. The “make or break” data is due out sometime next year.
There’s a new FDA warning on a potentially fatal skin rash that develops as a side effect from a Narcolepsy drug made by Cephelon (CEPH). Huckman suggests CEPH could trader lower on this news.